Decision and Details
Filing of a Form S-3 registration statement by Gyre Therapeutics, Inc.
This is a registration procedure under U.S. securities laws to enable Cullgen shareholders to sell in the future the Gyre shares issued to them as consideration for the acquisition of shares in connection with Cullgen becoming a wholly owned subsidiary, and is not intended to raise new funds.
No material impact on the Company's consolidated results is expected.
| Item | Details |
|---|---|
| Matter Covered | Filing of a Form S-3 registration statement by Gyre Therapeutics, Inc. |
| Decision Date | 23 June 2026 (the Form S-3 filing date) |
| Implementation Date | 23 June 2026 (filed) |
| Quantity / scale | The Company's effective ownership interest in Gyre shares: approximately 70% |
| Impact on Business Performance | No material impact on the Company's consolidated results is expected. |
| Reason | This is a registration procedure under U.S. securities laws to enable Cullgen shareholders to sell in the future the Gyre shares issued to them as consideration for the acquisition of shares in connection with Cullgen becoming a wholly owned subsidiary, and is not intended to raise new funds. |
| Governing Rule | U.S. securities laws |
| Related previous disclosures | Notice Regarding Gyre's Acquisition of All Shares of Cullgen Inc., dated 7 May 2026 |
| Future plans | A registration procedure intended to enable Cullgen shareholders to sell Gyre shares in the future. The specific timing of any sale is Not disclosed |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To enable Cullgen shareholders to sell in the future the Gyre shares issued as consideration for the acquisition of shares in connection with Cullgen becoming a wholly owned subsidiary.